Acute Respiratory Distress Syndrome Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, France, China - Size and Forecast 2024-2028

Published: Mar 2024 Pages: 161 SKU: IRTNTR77729

Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast 2024-2028

The global acute respiratory distress syndrome (ARDS) treatment market size is estimated to grow by USD 1.22 billion at a CAGR of 6.9% between 2023 and 2028. Our market growth and forecasting report examines historical data from 2018-2022 besides analyzing the current market scenario.

Moreover, healthcare providers are increasingly embracing lung-protective ventilation methods as standard ARDS patient care. These include using low tidal volumes, moderate to high PEEP, and driving pressure optimization to balance oxygenation and minimize ventilator-induced lung injury risks. Clinical guidelines from medical societies endorse these strategies, offering evidence-based recommendations for ventilation parameters and monitoring protocols. Advanced mechanical ventilators with tailored modes and monitoring capabilities further enhance lung-protective ventilation. These strategies, integrated into comprehensive ARDS management approaches, are expected to drive market growth.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by Distribution Channel, Route Of Administration and Geography Analysis

The market faces challenges like a lack of skilled professionals and trade regulations impacting drug prices and treatment costs. ARDS affects the lungs, leading to issues like fluid accumulation and susceptibility to sepsis and pneumonia due to inhalation of harmful substances. Symptoms include low blood pressure, shortness of breath, and rapid breathing. Treatments involve mechanical ventilation, IV fluids, and inhaled medications like nitric oxide and surfactants. The World Health Organization warns of rising air pollution and exposure to harmful gases.

Distribution Channel Analysis

The market share by the hospitals pharmacies segment will be significant during the forecast period. The demand for ARDS treatment through hospital pharmacies is directly linked to the number of patients requiring hospitalization for the condition. Factors such as ARDS prevalence, respiratory illness severity, and ICU admission rates dictate the volume of treatments dispensed.

Get a glance at the market contribution of various segments Download PDF Sample

The hospitals pharmacies segment was valued at USD 1.12 billion in 2018. Hospital pharmacies are crucial due to the accessibility of medications, respiratory support devices, and therapies needed for ARDS management. Additionally, they offer investigational and off-label therapies under healthcare provider supervision, ensuring timely access to ARDS treatments and supporting multidisciplinary care teams. This pivotal role will drive growth in the hospital pharmacies segment of the acute respiratory distress syndrome treatment market.

Route Of Administration Analysis

The oral?segment will account for the largest share of this segment.?Oral medications offer a convenient and non-invasive option for ARDS management, enabling patients to self-administer treatment at home or in outpatient settings. This reduces the need for frequent hospital visits and invasive procedures, enhancing patient compliance and therapeutic outcomes. Moreover, oral medications alleviate the burden on healthcare facilities, particularly in resource-limited settings, by reducing hospital admissions and healthcare costs. Flexibility in dosing regimens allows tailored treatment plans based on individual patient needs and preferences, driving growth in the oral segment of the market.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. North America faces a substantial burden of ARDS cases, driven by factors like aging populations, and rising incidences of pneumonia, sepsis, and trauma. The region's advanced healthcare infrastructure ensures early diagnosis and specialized treatment, improving patient outcomes. High healthcare expenditure, robust reimbursement policies, and government initiatives support access to ARDS therapies. For example, in 2023, the US government allocated USD 1.9 trillion to healthcare, while Canada announced a USD200 billion investment over ten years. Additionally, the increasing adoption of ECMO therapy enhances treatment options for severe ARDS cases.

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

  • Athersys Inc.: The company offers acute respiratory distress syndrome treatment such as SOLNATIDE peptide, a therapeutic peptide for the treatment of acute lung.

Air Liquide SA, Boston Scientific Corporation, Dragerwerk AG and Co. KGaA, Getinge AB, Koninklijke Philips N.V., LivaNova PLC, Medtronic, Nihon Kohden Corp., SCHILLER AG, Sleepnet Corp., Stryker Corp., Vyaire Medical Inc., Smiths Group Plc, ResMed Inc., Hamilton Medical AG, GE Healthcare Technologies Inc., Fisher and Paykel Healthcare Corp. Ltd., Edesa Biotech Inc., and APEPTICO Forschung und Entwicklung GmbH

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The acute respiratory distress syndrome (ARDS) treatment market is witnessing innovations like the SonarMed airway monitoring system to address challenges such as a Lack of Skilled Professionals and stringent Trade regulations affecting Drug prices and Treatment costs. ARDS, affecting the lungs and vital organs, is caused by factors like Sepsis, Pneumonia, or inhalation of harmful substances, leading to symptoms like Low blood pressure, Shortness of breath, and Rapid breathing. Treatment involves Mechanical ventilation, IV fluids, and Inhaled medications like Nitric oxide and Surfactants. As per the World Health Organization, rising air pollution and exposure to harmful gases contribute to ARDS prevalence. Our researchers analyzed the market research and growth data with 2023  as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage. 

Significant Trends

The growing interest in immunomodulatory therapies is the primary trend shaping the market. Immunomodulatory therapies are vital treatments that regulate the immune system's response in various medical conditions, including autoimmune diseases, infections, cancer, and organ transplantation. These therapies, aiming to either enhance or suppress immune activity, are integral components of multimodal treatment approaches for ARDS. Combining immunomodulation with standard ARDS treatments optimizes outcomes by addressing the complex nature of ARDS pathophysiology. Ongoing research focuses on identifying novel immunomodulatory agents and targets, including anti-inflammatory drugs, cytokine inhibitors, and biologic agents.

Furthermore, clinical trials evaluate the safety and efficacy of these therapies alone or in combination with standard treatments to improve patient outcomes. Advances in immunology uncover new therapeutic targets, such as pro-inflammatory cytokines and immune cell receptors, offering promising avenues for mitigating ARDS-associated inflammation and lung injury. The growing interest in immunomodulatory therapies underscores their potential to drive growth in the market.

Major Challenges

The heterogeneity of the patient population is the major challenge that affects market expansion. Managing ARDS patients presents challenges due to their heterogeneity in underlying causes, disease severity, and treatment responses. Developing effective therapies requires personalized or stratified treatment strategies, considering variations in age, sex, comorbidities, and disease etiology. Clinical trials must carefully account for patient heterogeneity to interpret results accurately. Comorbidities and pre-existing conditions further complicate treatment outcomes.

Additionally, patients may respond differently to standard therapies. Limited biomarkers hinder stratification and treatment decisions. Addressing ARDS heterogeneity demands personalized diagnostics, tailored treatment plans, and multidisciplinary care, posing challenges for healthcare systems. These factors will hinder the growth of the market during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

 Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • Distribution Channel Outlook
    • Hospitals pharmacies
    • Retail pharmacies
    • Online pharmacies
  • Route Of Administration Outlook
    • Oral
    • Injection
    • Inhalation
  • Region Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW)
      • Argentina
      • Australia
      • Brazil

Market Analyst Overview:

The global respiratory distress syndrome treatment market is witnessing significant growth, driven by rising disease prevalence and revenue growth. Technological advancements in ventilator strategies and endotracheal tube occlusion are enhancing patient care. Research and drug development, alongside government awareness campaigns, are pivotal in addressing challenges like fluid accumulation in alveoli. With home healthcare and specialty clinics playing crucial roles, critical care units are witnessing increased admissions. Acoustic technology and approved drugs further propel market trends.

Additionally, the global acute respiratory distress syndrome market is influenced by various factors, including healthcare investment and growth drivers. However, challenges such as lack of awareness hinder progress. Effective market segmentation aids in targeting specific end users, including private market key players and critical care unit admissions. Addressing issues like extreme tiredness requires innovative treatments and heightened awareness campaigns to improve patient outcomes and enhance the overall management of acute respiratory distress syndrome.

Acute Respiratory Distress Syndrome Treatment Market Scope

Report Coverage

Details

Page number

161

Base year

2023

Historic period

2018 - 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 6.9%

Market growth 2024-2028

USD 1.22 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

6.2

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 39%

Key countries

US, Germany, UK, France, and China

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

Air Liquide SA, Athersys Inc., Boston Scientific Corporation, Dragerwerk AG and Co. KGaA, Getinge AB, Koninklijke Philips N.V., LivaNova PLC, Medtronic, Nihon Kohden Corp., SCHILLER AG, Sleepnet Corp., Stryker Corp., Vyaire Medical Inc., Smiths Group Plc, ResMed Inc., Hamilton Medical AG, GE Healthcare Technologies Inc., Fisher and Paykel Healthcare Corp. Ltd., Edesa Biotech Inc., and APEPTICO Forschung und Entwicklung GmbH

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the between 2024 and 2028
  • Precise estimation of the size and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies' position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global acute respiratory distress syndrome treatment market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global acute respiratory distress syndrome treatment market 2018 - 2022 ($ billion)
    • 4.2 Distribution Channel Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ billion)
    • 4.3 Route of Administration Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Route of Administration Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Distribution Channel

    • 6.1 Market segments
      • Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
    • 6.2 Comparison by Distribution Channel
      • Exhibit 32: Chart on Comparison by Distribution Channel
      • Exhibit 33: Data Table on Comparison by Distribution Channel
    • 6.3 Hospitals pharmacies - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Hospitals pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Hospitals pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Hospitals pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Hospitals pharmacies - Year-over-year growth 2023-2028 (%)
    • 6.4 Retail pharmacies - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
    • 6.5 Online pharmacies - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by Distribution Channel
      • Exhibit 46: Market opportunity by Distribution Channel ($ billion)
      • Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ billion)

    7 Market Segmentation by Route of Administration

    • 7.1 Market segments
      • Exhibit 48: Chart on Route of Administration - Market share 2023-2028 (%)
      • Exhibit 49: Data Table on Route of Administration - Market share 2023-2028 (%)
    • 7.2 Comparison by Route of Administration
      • Exhibit 50: Chart on Comparison by Route of Administration
      • Exhibit 51: Data Table on Comparison by Route of Administration
    • 7.3 Oral - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on Oral - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Oral - Year-over-year growth 2023-2028 (%)
    • 7.4 Injection - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Injection - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on Injection - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on Injection - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Injection - Year-over-year growth 2023-2028 (%)
    • 7.5 Inhalation - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Inhalation - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 61: Data Table on Inhalation - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 62: Chart on Inhalation - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Inhalation - Year-over-year growth 2023-2028 (%)
    • 7.6 Market opportunity by Route of Administration
      • Exhibit 64: Market opportunity by Route of Administration ($ billion)
      • Exhibit 65: Data Table on Market opportunity by Route of Administration ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 China - Market size and forecast 2023-2028
      • Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.9 Germany - Market size and forecast 2023-2028
      • Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.10 UK - Market size and forecast 2023-2028
      • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.11 France - Market size and forecast 2023-2028
      • Exhibit 103: Chart on France - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 105: Chart on France - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on France - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ billion)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 APEPTICO Forschung und Entwicklung GmbH
              • Exhibit 115: APEPTICO Forschung und Entwicklung GmbH - Overview
              • Exhibit 116: APEPTICO Forschung und Entwicklung GmbH - Product / Service
              • Exhibit 117: APEPTICO Forschung und Entwicklung GmbH - Key offerings
            • 12.4 Athersys Inc.
              • Exhibit 118: Athersys Inc. - Overview
              • Exhibit 119: Athersys Inc. - Product / Service
              • Exhibit 120: Athersys Inc. - Key offerings
            • 12.5 Dragerwerk AG and Co. KGaA
              • Exhibit 121: Dragerwerk AG and Co. KGaA - Overview
              • Exhibit 122: Dragerwerk AG and Co. KGaA - Business segments
              • Exhibit 123: Dragerwerk AG and Co. KGaA - Key offerings
              • Exhibit 124: Dragerwerk AG and Co. KGaA - Segment focus
            • 12.6 Edesa Biotech Inc.
              • Exhibit 125: Edesa Biotech Inc. - Overview
              • Exhibit 126: Edesa Biotech Inc. - Product / Service
              • Exhibit 127: Edesa Biotech Inc. - Key offerings
            • 12.7 Fisher and Paykel Healthcare Corp. Ltd.
              • Exhibit 128: Fisher and Paykel Healthcare Corp. Ltd. - Overview
              • Exhibit 129: Fisher and Paykel Healthcare Corp. Ltd. - Product / Service
              • Exhibit 130: Fisher and Paykel Healthcare Corp. Ltd. - Key news
              • Exhibit 131: Fisher and Paykel Healthcare Corp. Ltd. - Key offerings
            • 12.8 GE Healthcare Technologies Inc.
              • Exhibit 132: GE Healthcare Technologies Inc. - Overview
              • Exhibit 133: GE Healthcare Technologies Inc. - Business segments
              • Exhibit 134: GE Healthcare Technologies Inc. - Key news
              • Exhibit 135: GE Healthcare Technologies Inc. - Key offerings
              • Exhibit 136: GE Healthcare Technologies Inc. - Segment focus
            • 12.9 Getinge AB
              • Exhibit 137: Getinge AB - Overview
              • Exhibit 138: Getinge AB - Business segments
              • Exhibit 139: Getinge AB - Key news
              • Exhibit 140: Getinge AB - Key offerings
              • Exhibit 141: Getinge AB - Segment focus
            • 12.10 Hamilton Medical AG
              • Exhibit 142: Hamilton Medical AG - Overview
              • Exhibit 143: Hamilton Medical AG - Product / Service
              • Exhibit 144: Hamilton Medical AG - Key offerings
            • 12.11 Koninklijke Philips N.V.
              • Exhibit 145: Koninklijke Philips N.V. - Overview
              • Exhibit 146: Koninklijke Philips N.V. - Business segments
              • Exhibit 147: Koninklijke Philips N.V. - Key news
              • Exhibit 148: Koninklijke Philips N.V. - Key offerings
              • Exhibit 149: Koninklijke Philips N.V. - Segment focus
            • 12.12 LivaNova PLC
              • Exhibit 150: LivaNova PLC - Overview
              • Exhibit 151: LivaNova PLC - Business segments
              • Exhibit 152: LivaNova PLC - Key news
              • Exhibit 153: LivaNova PLC - Key offerings
              • Exhibit 154: LivaNova PLC - Segment focus
            • 12.13 Medtronic
              • Exhibit 155: Medtronic - Overview
              • Exhibit 156: Medtronic - Business segments
              • Exhibit 157: Medtronic - Key news
              • Exhibit 158: Medtronic - Key offerings
              • Exhibit 159: Medtronic - Segment focus
            • 12.14 Nihon Kohden Corp.
              • Exhibit 160: Nihon Kohden Corp. - Overview
              • Exhibit 161: Nihon Kohden Corp. - Product / Service
              • Exhibit 162: Nihon Kohden Corp. - Key offerings
            • 12.15 ResMed Inc.
              • Exhibit 163: ResMed Inc. - Overview
              • Exhibit 164: ResMed Inc. - Business segments
              • Exhibit 165: ResMed Inc. - Key news
              • Exhibit 166: ResMed Inc. - Key offerings
              • Exhibit 167: ResMed Inc. - Segment focus
            • 12.16 Smiths Group Plc
              • Exhibit 168: Smiths Group Plc - Overview
              • Exhibit 169: Smiths Group Plc - Business segments
              • Exhibit 170: Smiths Group Plc - Key news
              • Exhibit 171: Smiths Group Plc - Key offerings
              • Exhibit 172: Smiths Group Plc - Segment focus
            • 12.17 Vyaire Medical Inc.
              • Exhibit 173: Vyaire Medical Inc. - Overview
              • Exhibit 174: Vyaire Medical Inc. - Product / Service
              • Exhibit 175: Vyaire Medical Inc. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 176: Inclusions checklist
                • Exhibit 177: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 178: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 179: Research methodology
                • Exhibit 180: Validation techniques employed for market sizing
                • Exhibit 181: Information sources
              • 13.5 List of abbreviations
                • Exhibit 182: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              acute respiratory distress syndrome treatment market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis